Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736293 · ClinicalTrials.gov registry record
Natural History of Eye Diseases Related to ABCA4 Mutations
A clinical trial of Retinal Degeneration and ABCA4-Related Retinopathies, sponsored by National Eye Institute (NEI).
- Active
- Registry status
- 68
- Enrollment target
- 1
- Study location
NCT01736293 is a study of Retinal Degeneration and ABCA4-Related Retinopathies that is active but no longer recruiting, run by National Eye Institute (NEI). The registered enrollment target is 68 participants, below the 337-participant average among 17 other Retinal Degeneration trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01736293, a study of Retinal Degeneration and ABCA4-Related Retinopathies, is active but no longer recruiting, sponsored by National Eye Institute (NEI).
- ACTIVE NOT RECRUITING
- Registry status
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- The ABCA4 gene contains a blueprint for the ABCA4 protein. When this protein is absent or faulty (such as in Stargardt s disease), waste material from dead cells collects in the eye. The waste material may cause other cells in the eye to die. This can lead to the loss of vision. Researchers want to look at blood and skin samples from people with ABCA4 gene mutations to study related eye diseases. Objectives: \- To study eye diseases that are related to mutations in the ABCA4 gene. Eligibility: \- Individuals at least 12 years of age who have ABCA4 gene mutations. Design: * The study requires 12 visits to the National Eye Institute clinic over 10 years. In the first year, there will be three visits. After the first year, participants will have one visit a year for 9 more years. * Participants will be screened with a physical exam, full eye exam, and medical history. The eye exam will check eye pressure, light and color sensitivity, and retina function. * Participants will provide a blood sample and a skin tissue sample for study. * No treatment will be provided as part of this study.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2012-10-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01736293
The ClinicalTrials.gov registry entry for NCT01736293 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 337-participant average among 17 other Retinal Degeneration trials with a reported enrollment target (80% lower). The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Retinal Degeneration appearing as the primary indexed condition, and to 0 interventions.
NCT01736293 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01736293 about?
NCT01736293 is a clinical study titled "Natural History of Eye Diseases Related to ABCA4 Mutations". Background: \- The ABCA4 gene contains a blueprint for the ABCA4 protein. When this protein is absent or faulty (such as in Stargardt s disease), waste material from dead cells collects in the eye. The waste material may cause other cells in the eye to die. This can lead to the loss of vision. Rese...
What is the current status of trial NCT01736293?
This trial is currently active not recruiting. The enrollment target is 68 participants. The study started on 2012-10-09.
What conditions does trial NCT01736293 study?
This clinical trial studies the following conditions: Retinal Degeneration, ABCA4-Related Retinopathies.
Who is sponsoring clinical trial NCT01736293?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01736293 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
Cell Collection to Study Eye Diseases
RECRUITING
-
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
RECRUITING · Phase 1
-
Adaptive Optics Imaging of Outer Retinal Diseases
RECRUITING
-
Rod and Cone Mediated Function in Retinal Disease
RECRUITING
-
Oral Metformin for Treatment of ABCA4 Retinopathy
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.